Leviticus Partners LP 13D and 13G filings for Harvard Bioscience, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-03-17 10:33 am Purchase | 2025-03-14 | 13G | Harvard Bioscience, Inc. HBIO | Leviticus Partners LP | 3,284,535 7.500% | 1,139,644 (+53.13%) | Filing |
| 2025-02-04 10:37 am Sale | 2025-02-03 | 13G | Harvard Bioscience, Inc. HBIO | Leviticus Partners LP | 2,144,891 4.900% | -163,731 (-7.09%) | Filing |
| 2024-03-19 1:02 pm Purchase | 2024-03-18 | 13G | Harvard Bioscience, Inc. HBIO | Leviticus Partners LP | 2,308,622 5.320% | 201,952 (+9.59%) | Filing |
| 2024-01-22 10:55 am Sale | 2024-01-16 | 13G | Harvard Bioscience, Inc. HBIO | Leviticus Partners LP | 2,106,670 4.940% | -52,124 (-2.41%) | Filing |
| 2023-08-28 3:07 pm Purchase | 2023-08-25 | 13G | Harvard Bioscience, Inc. HBIO | Leviticus Partners LP | 2,158,794 5.060% | 104,887 (+5.11%) | Filing |
| 2023-01-11 1:30 pm Sale | 2023-01-06 | 13G | Harvard Bioscience, Inc. HBIO | Leviticus Partners LP | 2,053,907 4.930% | -200,000 (-8.87%) | Filing |
| 2022-12-21 4:20 pm Purchase | 2022-12-16 | 13G | Harvard Bioscience, Inc. HBIO | Leviticus Partners LP | 2,253,907 5.410% | 2,253,907 (New Position) | Filing |